BTK and B-cell chronic lymphocytic leukemia: Notably, ibrutinib but not acalabrutinib significantly impairs ADCP of rituximab-opsonized CLL cells by human macrophages, suggesting a BTK-independent mechanism of action (Borge et al., 2015; Da Roit et al., 2015; Golay et al., 2017).